An observational study in Respiratory Distress Syndrome (RDS) and Respiratory Failure, sponsored by University of Padova. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by University of Padova · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Respiratory Distress Syndrome with a site in Italy — 21 open to participants now, 24 under way, 2 of them phase 3. Respiratory Distress Syndrome · Italy.
Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, this one is the 30th largest by planned enrollment of the 39 observational ones that give a count, is one of 2 that started in 2025, is one of 40 observational ones, reaches primary completion later than 22 of the 23 other live ones, and was the 88th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →21 of the 91 studies in Respiratory Distress Syndrome with a site in Italy are open now. Recruiting first, the newest first:
Istituto Clinico Humanitas · Sites in Italy
Ages 18+
University College Dublin · Sites in Italy, Croatia, Czechia and 6 more countries
Ages 0 min–28 days
University of Bologna · Sites in Italy
Ages 18–100
BioAegis Therapeutics Inc. · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 11
First in 2002; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 49 interventional studies, 110 across the 39 observational. Of the 49 that completed or were terminated, 6 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 91 have an industry lead sponsor. The 10 most frequent:
University of Padova is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
University of Padova has 6 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
11 of the studies in Respiratory Distress Syndrome with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04460859Unity Health TorontoRecruitmEnt Assessed by eleCtRical Impedance Tomography | 2026-12 |
| NCT07402174Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoEIT- Guided Lung Recruitment in pARDS | 2026-12-01 |
| NCT07686315Istituto Clinico HumanitasAdvanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure | 2026-12-30 |
| NCT04903262University of BolognaUltra-Protective Lung Ventilation With Extracorporeal CO2 Removal for Moderate ARDS | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Acute Respiratory Distress Syndrome (ARDS) is a systemic syndrome characterized by severe respiratory failure, inflammation, loss of aerated tissue and high mortality. Recently, significant efforts have been made to phenotype ARDS patients through a wide range of new biomarkers and imaging indices with the goal of developing personalized treatments based on patient's biophenotypization. Recent literature demonstrates, both in vitro and in vivo but not yet in ARDS patients, that the serine protease inhibitor(SERPIN)-B3 plays a crucial role in the pathological mechanism of pulmonary fibrogenesis, and, similarly, protease-activated receptors(PAR2) is highly involved in this aberrant inflammatory response.
Consequently, studying the expression of SERPINB3 (including SCCA-PD polymorphism) and PAR2, in association with a detailed clinical and biomolecular phenotypization, could allow new insights into the pathophysiological mechanisms of lung injury during ARDS.
SERPINB3 is a strong activator of transforming growth factor-beta (TGF-b), an important pro-fibrogenic cytokine that also promotes epithelial-mesenchymal transition. Its expression can be induced/stimulated by oxidative stress. For example, in patients with idiopathic pulmonary fibrosis, the expression of SERPINB3 is significantly correlated with the presence of severe fibrosis and the expression of TGF-b. Recently, a new polymorphism of SERPINB3 (SCCA-PD) has been identified, featuring a single amino acid substitution in the reactive center loop of the protein, which enhances the functional anti-protease activity of this protein, inducing a more pronounced inflammatory and fibrotic response compared to wild-type SERPINB3, even in cultured monocytic cell lines. However, data is lacking in patients affected by ARDS. Furthermore, the reactive site loop of SERPINB3 has been shown to be essential for activating PAR2, another key element in the pro-fibrogenic cascade. PAR2 belongs to a subfamily of protease-activated G-protein-coupled receptors, consisting of four members, which plays a crucial role not only in activating the coagulation cascade and endothelendothelial inflammation but also in other stress-related clinical responses, such as pulmonary fibrosis. In conclusion, there is currently no data confirming a potential activation of the "SERPINB3-PAR2" pathway in ARDS patient, which is presumably involved in the pathway of severe lung injuries affecting ARDS patients.
More severe hyperinflammatory subphenotypes of ARDS are presumibely correlated with higher expression of SERPINB3, PAR2 and the presence of the SCCA-PD polymorphism. Thus, an early phenotypization of these critically ill patients could:
i) allow the identification and characterization of a subgroup of patients at higher risk of pulmonary fibrosis and death; and, ii) promote the development of new therapeutic strategies, that counteract the fibroproliferative process during ARDS avoiding the activation of "SERPINB3-PAR2" pathway, which could be a new pharmacological target for limiting the aberrant lung injury affecting ARDS patients (see 1-PPA).
Demographic, clinical, and ventilatory data will be collected in accordance with our institutional protocols until hospital discharge. All patients will undergo a high-resolution chest CT scan within 72 hours of ARDS diagnosis using a multidetector CT scan to assess the fibroproliferative changes typical of pulmonary fibrosis. A second high-resolution CT scan will be performed 21 ± 7 days after ARDS diagnosis or at hospital discharge, whichever occurs first, to monitor the evolution of fibroproliferative pulmonary changes.
Blood samples and BAL samples will be collected within 72 hours (and, only if available, at 21 ± 7 days) from ARDS diagnosis, as part of routine clinical practice. Only residual material will be used for research purposes.
Adult patients affected by ARDS and requiring IMV
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients affected by Acute Respiratory Distress Syndrome (ARDS) and needing invasive mechanical ventilation (IMV).
Patients admitted to the Intensive Care Unit and requiring IMV not for respiratory reasons.
SERPINB3
Quantifying the expression of SERPINB3, PAR2 (measured in blood, bronchoalveolare lavage (BAL), and extracellular vesicles (EV)) in adult ARDS patients, requiring ventilatory support.
Time frame: Within 72 hours from ARDS diagnosis
SCCA-PD
Quantifying the occurrence of SCCA-PD variant in adult ARDS patients, requiring ventilatory support.
Time frame: Within 72 hours from ARDS diagnosis
FIBROSIS and SERPINB3, PAR2, SCCA-PD variant
Investigating potential correlations between the Ichikado score (calculated on the CTscan performed after 21±7 days from ARDS diagnosis) and the expression of SERPINB3, PAR2 and the SCCA-PD variant.
Time frame: At 21 days from ARDS diagnosis
60-DAY MORTALITY PREDICITVE MODELS
Subsequently, identifying new models able to predict 60-day mortality according to anthropometric, clinical, respiratory parameters and laboratory data of lung damage (i.e., SERPINB3, PAR2, inflammatory cytokines (including TNF-a, TGF-ß ect) and cytofluorimetric measurements).
Time frame: At 60-day after ARDS diagnosis
Only if available
Quantifying the expression of SERPINB3, PAR2 (measured in blood, bronchoalveolare lavage (BAL), and extracellular vesicles (EV)) in adult ARDS patients, requiring ventilatory support.
Time frame: At 21 days after ARDS diagnosis
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2028, 46 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 46 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →